エドワーズライフサイエンスに関するコメント

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $アライン・テクノロジー(ALGN.US)$ - up 11.5%
2. $テクストロン(TXT.US)$ - up 5.2%
3. $STマイクロエレクトロニクス(STM.US)$ - up 4.1%
4. $ラムリサーチ(LRCX.US)$ - up 3.9%
5. $レレックス(RELX.US)$ - up 3.1%
6. $ロイヤル・カリビアン・グループ(RCL.US)$ - up 3.1%
7. $マイクロン テクノロジー(MU.US)$ - up 3.1%
8. $ウエスタンデジタル(WDC.US)$ - up 2.9...

Pre-Market Stock Movers
Gapping up
$アライン・テクノロジー(ALGN.US)$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$メタ・プラットフォームズ(META.US)$
(The Facebook parent jumped ne...

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $スミス・アンド・ネフュー(SNN.US)$ - up 4.3%
2. $コヒレント(COHR.US)$ - up 4.1%
3. $トヨタ自動車(TM.US)$ - up 3.2%
4. $ジンマー・バイオメット・ホールディングス(ZBH.US)$ - up 2.9%
5. $アイ・ピー・ジーフォトニクス(IPGP.US)$ - up 2.8%
6. $ストライカー(SYK.US)$ - up 2.8%
7. $ユニバーサル・ヘルス・サービシズ(UHS.US)$ - up 2....

QUICK SCALP 91 $EW — STOCK & OPTION PLAY
ALERT ON: $91.06
ON THE WATCH: $91.18
🥇 SIGNED OF MORE UPTREND: $91.28
NEED IT TO BREAK OVER: $91.33
key indicator for MORE uptrend $91.45
confirmation uptrend - $91.55
OK I SEE YOU -  $91.64
mini breakout - $91.78
Prepare for bigger breakout: $91.91. $エドワーズライフサイエンス(EW.US)$

Tesla Is Downgraded at Berenberg With the Rally Expected to Cool Off
$テスラ(TSLA.US)$ slipped in early trading on Wednesday after Berenberg turned cautious on the stock. The firm cuts its rating to Hold from Buy on its view the recent rally now has the share price reflecting misplaced fears over an electric vehicle price war.
UOB Kay Hian Upgrades Sea to Buy
UOB Kay Hian analysts John Cheong, Jacquelyn Yow and Heidi Mo have upgraded their ...

FibroGen Upgraded to Outperform at William Blair on Pamrevlumab's Potential
William Blair analyst Andy Hsieh upgraded $ファイブロジェン(FGEN.US)$ to Outperform from Market Perform following a deep dive on the potential of pamrevlumab, the company's wholly owned monoclonal antibody against connective tissue growth factor, which is being evaluated in the treatment of idiopathic pulmonary fibrosis, or IPF, locally advanced pancreatic cancer, or LAP...